Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Blacksburg Neurology PC

Neither a doctor nor a teaching hospital

Research payments

$113,617

227 payments

Through program year 2025, Blacksburg Neurology PC is reported as receiving $113,617 in research payments, across 227 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $11,249 37
2024 Research $18,856 70
2023 Research $15,848 62
2022 Research $30,064 28
2021 Research $29,784 20
2020 Research $7,556 9
2019 Research $261 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Roche Products Limited $85,335 160 payments
  2. EMD Serono, Inc. $28,282 67 payments
Studies the money was for Research payments · program years 2019–2025
  1. Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment $85,335 160 payments
  2. Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) $11,987 30 payments
  3. Observational evaluation of effectiveness and patient-reported outcomeS (PROs) in suboPtimally controlled patients previously taking injectable disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) $4,329 12 payments
  4. Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) $3,000 1 payment
  5. Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) $2,144 8 payments
  6. Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) $1,986 7 payments
  7. Observational evaluation of effectiveness and patient-reported outcomeS (PROs) in suboPtimally controlled patients previously taking injectable disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) $1,976 3 payments
  8. Observational evaluation of effectiveness and patient-reported outcomeS (PROs) in suboPtimally controlled patients previously taking injectable disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) $1,399 4 payments
  9. Observational evaluation of effectiveness and patient-reported outcomeS (PROs) in suboPtimally controlled patients previously taking injectable disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) $1,200 1 payment
  10. Ms700568-0079 $261 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record